GENEMATRIX INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,500 KRW | -0.60% |
|
0.00% | -19.48% |
| 2023 | GeneMatrix Inc.(KOSDAQ:A109820) dropped from S&P Global BMI Index | CI |
| 2021 | GeneMatrix Inc.(KOSDAQ:A109820) added to S&P Global BMI Index | CI |
| Sales 2017 | 5.19B 3.77M | Sales 2018 | 4.73B 3.44M | Capitalization | 67.83B 49.31M |
|---|---|---|---|---|---|
| Net income 2017 | -1.47B -1.07M | Net income 2018 | -3.11B -2.26M | EV / Sales 2017 | 6.33 x |
| Net cash position 2017 | 3.55B 2.58M | Net Debt 2018 | 1.93B 1.41M | EV / Sales 2018 | 14.7 x |
| P/E ratio 2017 |
-24.8
x | P/E ratio 2018 |
-20.9
x | Employees | 31 |
| Yield 2017 * |
-
| Yield 2018 |
-
| Free-Float | 81.94% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.59% | ||
| 1 week | +0.60% | ||
| Current month | -10.18% | ||
| 1 month | -14.75% | ||
| 3 months | -5.09% | ||
| 6 months | +0.20% | ||
| Current year | -19.00% |
1 week
2 470.00
2 560.00
1 month
2 460.003 090.00
Current year
2 385.003 575.00
1 year
2 380.005 490.00
3 years
2 380.0023 350.00
5 years
2 005.0035 500.00
10 years
1 586.6735 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Soo-Ok Kim
CEO | Chief Executive Officer | 63 | 00-12-06 |
Suk-Joon Kim
BRD | Director/Board Member | 56 | - |
Sun-Pyo Hong
BRD | Director/Board Member | 55 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mahn-Soon Hwang
BRD | Director/Board Member | 54 | - |
Soo-Ok Kim
CEO | Chief Executive Officer | 63 | 00-12-06 |
Sun-Pyo Hong
BRD | Director/Board Member | 55 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 2,500 | -0.60% | 31 509 |
| 24-04-25 | 2,515 | -0.59% | 27,642 |
| 24-04-24 | 2,530 | +0.80% | 12,693 |
| 24-04-23 | 2,510 | +0.20% | 16,937 |
| 24-04-22 | 2,505 | +0.20% | 11,377 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
GENEMATRIX Inc. is a Korea-based company mainly engaged in biotechnology business. The Company operates in two segments: pharmaceutical development and diagnostic medicine. Its pharmaceutical development segment specializes in the development of restriction fragment mass polymorphism (RFMP) genotyping technology for diagnosis of hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV) and others. Its diagnostic medicine segment specializes in the manufacture and sale of liver-function examination reagents, and import and sale of medical equipment and reagents.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -19.00% | 37.34M | |
| +2.07% | 42.59B | |
| +7.09% | 40.65B | |
| +49.00% | 40.57B | |
| -11.96% | 26.77B | |
| +8.56% | 24.81B | |
| -23.81% | 18.17B | |
| +27.11% | 12.05B | |
| -2.99% | 11.7B | |
| +7.02% | 11.1B |
- Stock Market
- Equities
- A109820 Stock
